Research Article
Prognostic Value of HPV E6 and APOBEC3B in Upper Urinary Tract Urothelial Carcinoma
Table 1
Correlation between E6/APOBEC3B expression and clinical characteristics in 78 UTUC patients.
| | Clinic pathological features | All case | HPV E6 expression | APOBEC3B expression | | Negative | Positive | value | Low | High | value |
| | Median age, years (range) | 70 (47-91) | 72 (47-91) | 70 (49-85) | 0.434 | 72 (48-91) | 69 (47-85) | 0.564 | | Sex,(%) | | | Male | 52 (66.67) | 31 (39.74) | 21 (26.92) | 0.078 | 34 (43.59) | 18 (23.08) | 0.191 | | Female | 26 (33.33) | 10 (12.82) | 16 (20.51) | 13 (16.66) | 13 (16.66) | | Smoking,(%) | | | Yes | 33 (42.31) | 19 (24.36) | 14 (17.95) | 0.448 | 20 (25.64) | 13 (16.66) | 0.956 | | No | 45 (57.69) | 22 (28.21) | 23 (29.48) | 27 (34.61) | 18 (23.08) | | Tumor location,(%) | | | Calix or pelvis | 47 (60.26) | 27 (34.62) | 20 (25.64) | 0.288 | 31 (39.74) | 16 (20.51) | 0.205 | | Ureter | 31 (39.74) | 14 (17.95) | 17 (21.79) | 16 (20.51) | 15 (19.23) | | Pathological T stage,(%) | | | pTa | 10 (12.82) | 2 (2.56) | 8 (10.26) | 0.045 | 5 (6.41) | 5 (6.41) | 0.267 | | pT1 | 23 (29.49) | 10 (12.82) | 13 (16.67) | 12 (15.38) | 11 (14.10) | | pT2 | 9 (11.54) | 5 (6.41) | 4 (5.13) | 7 (8.97) | 2 (2.56) | | pT3 | 21 (26.92) | 12 (15.38) | 9 (11.54) | 11 (14.10) | 10 (12.82) | | pT4 | 15 (19.23) | 12 (15.38) | 3 (3.85) | 12 (15.38) | 3 (3.85) | | Pathological N stage,(%) | | | pNx or pN0 | 73 (93.59) | 37 (47.43) | 36 (46.16) | 0.420 | 43 (55.13) | 30 (38.46) | 0.645 | | pN1-2 | 5 (6.41) | 4 (5.13) | 1 (1.28) | 4 (5.13) | 1 (1.28) | | Tumor stage AJCC staging,(%) | | | I | 32 (41.03) | 12 (15.38) | 20 (25.64) | 0.012 | 15 (19.23) | 17 (21.79) | 0.034 | | II | 8 (10.26) | 2 (2.56) | 6 (7.69) | 3(3.85) | 5 (6.41) | | III | 21 (26.92) | 14 (17.95) | 7 (8.97) | 15 (19.23) | 6 (7.69) | | IV | 17 (21.79) | 13 (16.66) | 4 (5.13) | 14 (17.95) | 3 (3.85) | | Tumor grade,(%) | | | Low | 14 (17.95) | 4 (5.13) | 10 (12.82) | 0.047 | 4 (5.13) | 10 (12.82) | 0.007 | | High | 64 (82.05) | 37 (47.43) | 27 (34.62) | 43 (55.13) | 21 (26.92) | | LVI,(%) | | | Yes | 16 (20.51) | 12 (15.38) | 4 (5.13) | 0.044 | 11 (14.10) | 5 (6.41) | 0.436 | | No | 62 (79.49) | 29 (37.18) | 33 (42.31) | 36 (46.16) | 26 (33.33) |
|
|
